Document Detail

Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia†.
MedLine Citation:
PMID:  22233429     Owner:  NLM     Status:  In-Data-Review    
Dasatinib (Sprycel®) is an orally administered small molecule inhibitor of multiple tyrosine kinases, including BCR-ABL and SRC family kinases, which is indicated for the treatment of adults with newly diagnosed chronic-phase chronic myeloid leukemia (CML), CML (chronic-, accelerated- or blast-phase) with resistance or intolerance to prior therapy, including imatinib, or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy. Dasatinib is ≈325-fold more active than imatinib in inhibiting wild-type BCR-ABL kinase in vitro and is active against a wide variety of imatinib-resistant BCR-ABL mutants, except for T315I. This article reviews the efficacy and tolerability of dasatinib in the treatment of patients with newly diagnosed chronic-phase CML or imatinib-resistant or -intolerant CML or Ph+ ALL, as well as summarizing its pharmacologic properties. In clinical trials, oral dasatinib was effective in achieving major or complete cytogenetic responses in both newly diagnosed and imatinib-resistant or -intolerant chronic-phase CML. Dasatinib was likewise effective in achieving major or overall hematologic responses in imatinib-resistant or -intolerant, accelerated- or blast-phase CML, or Ph+ ALL. Responses were rapidly achieved within 1-3 months and were durable over 1-5 years of follow-up. The majority of adverse events with dasatinib were of mild or moderate severity. Fluid retention (including pleural effusion) was the most common adverse event. Hematologic abnormalities were common and cytopenias were the most common grade 3/4 adverse events. Dasatinib 100 mg administered once daily was as effective as dasatinib 70 mg administered twice daily, and was better tolerated, being associated with lower incidences of pleural effusion and grade 3/4 thrombocytopenia, in particular. Dasatinib was more effective than high-dose imatinib in the treatment of patients with imatinib-resistant chronic-phase CML and was more effective than standard dosages of imatinib, as well as being associated with less frequent fluid retention, in patients with newly diagnosed chronic-phase CML. Dasatinib was generally equally effective in patients with or without BCR-ABL mutations at baseline. Therefore, oral dasatinib is a highly effective, once-daily therapy for the first-line treatment of newly diagnosed patients with chronic-phase CML, as well as for the treatment of patients with imatinib-resistant or -intolerant chronic- and advanced-phase CML or Ph+ ALL. †Adapted and reproduced from the original article published in Drugs 2011; 71 (13): 1771-1795.
Paul L McCormack; Susan J Keam
Related Documents :
19065439 - Pulmonary hypertension in beta-thalassemia major and the role of l-carnitine therapy.
16181149 - Diastolic dysfunction is associated with anaemia in patients with type ii diabetes.
8217449 - Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syn...
20795769 - Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with ...
10083969 - Blunt cardiac rupture.
15385749 - Cardiac troponin elevations among critically ill patients.
8586369 - Duodenogastric and non acid gastro-oesophageal reflux in patients with reflux oesophagi...
16289309 - Thrombolytic therapy in acute ischemic stroke in asia: the first prospective evaluation.
22736319 - Acute liver failure secondary to gemcitabine.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy     Volume:  26     ISSN:  1173-8804     ISO Abbreviation:  BioDrugs     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705305     Medline TA:  BioDrugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  61-4     Citation Subset:  IM    
Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patterns of plant subcellular responses to successful oomycete infections reveal differences in host...
Next Document:  Turnover of New Graduate Nurses in Their First Job Using Survival Analysis.